Amneal Pharmaceuticals, Inc.
AMRX
$7.40
-$0.41-5.25%
| Weiss Ratings | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.98 | |||
| Price History | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -11.42% | |||
| 30-Day Total Return | -5.43% | |||
| 60-Day Total Return | -5.91% | |||
| 90-Day Total Return | -11.00% | |||
| Year to Date Total Return | -4.57% | |||
| 1-Year Total Return | 24.24% | |||
| 2-Year Total Return | 444.49% | |||
| 3-Year Total Return | 75.06% | |||
| 5-Year Total Return | 135.83% | |||
| 52-Week High % Change | -17.57% | |||
| 52-Week Low % Change | 50.77% | |||
| Price | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $9.48 | |||
| 52-Week Low Price | $5.18 | |||
| 52-Week Low Price (Date) | Apr 22, 2024 | |||
| 52-Week High Price (Date) | Nov 12, 2024 | |||
| Valuation | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.42B | |||
| Enterprise Value | 4.97B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.38 | |||
| Earnings Per Share Growth | 20.20% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.87 | |||
| Price/Book (Q) | -22.15 | |||
| Enterprise Value/Revenue (TTM) | 1.78 | |||
| Price | $7.41 | |||
| Enterprise Value/EBITDA (TTM) | 8.50 | |||
| Enterprise Value/EBIT | 14.26 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 309.85M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 908 947 3120 | |||
| Address | 400 Crossing Boulevard Bridgewater, NJ 08807 | |||
| Website | www.amneal.com | |||
| Country | United States | |||
| Year Founded | 2002 | |||
| Profitability | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 12.46% | |||
| Profit Margin | -4.18% | |||
| Management Effectiveness | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 6.24% | |||
| Return on Equity | -- | |||
| Income Statement | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 2.79B | |||
| Total Revenue (TTM) | 2.79B | |||
| Revenue Per Share | $9.02 | |||
| Gross Profit (TTM) | 1.02B | |||
| EBITDA (TTM) | 584.55M | |||
| EBIT (TTM) | 348.36M | |||
| Net Income (TTM) | -116.89M | |||
| Net Income Avl. to Common (TTM) | -116.89M | |||
| Total Revenue Growth (Q YOY) | 18.40% | |||
| Earnings Growth (Q YOY) | 77.78% | |||
| EPS Diluted (TTM) | -0.38 | |||
| EPS Diluted Growth (Q YOY) | 75.22% | |||
| Balance Sheet | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 112.42M | |||
| Cash Per Share (Q) | $0.36 | |||
| Total Current Assets (Q) | 1.59B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -44.54M | |||
| Current Ratio (Q) | 1.405 | |||
| Book Value Per Share (Q) | -$0.35 | |||
| Total Assets (Q) | 3.50B | |||
| Total Current Liabilities (Q) | 1.13B | |||
| Total Debt (Q) | 2.59B | |||
| Total Liabilities (Q) | 3.55B | |||
| Total Common Equity (Q) | -109.27M | |||
| Cash Flow | AMRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -63.00M | |||
| Cash from Financing (TTM) | -211.79M | |||
| Net Change in Cash (TTM) | 19.31M | |||
| Levered Free Cash Flow (TTM) | 239.62M | |||
| Cash from Operations (TTM) | 295.10M | |||
